ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6195
0.07%
Brent Oil
83.76
0.00%
Bitcoin
66,142.14
-1.19%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Akcea Therapeutics Inc (AKCA)

  7. Akcea Therapeutics Inc (AKCA) Noticias

AKCA

Akcea Therapeutics (AKCA)

Akcea Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AKCA
FechaHoraFuenteTítuloSímboloCompañía
10/11/202009:28Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AKCAAkcea Therapeutics Inc
30/10/202006:00PR Newswire (US)Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology ProductNASDAQ:AKCAAkcea Therapeutics Inc
23/10/202007:00Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:AKCAAkcea Therapeutics Inc
14/10/202015:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AKCAAkcea Therapeutics Inc
13/10/202007:59Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AKCAAkcea Therapeutics Inc
13/10/202007:52Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:AKCAAkcea Therapeutics Inc
13/10/202007:48Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:AKCAAkcea Therapeutics Inc
13/10/202007:47Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AKCAAkcea Therapeutics Inc
13/10/202007:42Edgar (US Regulatory)Amended Statement of Ownership: Private Transaction (sc 13e3/a)NASDAQ:AKCAAkcea Therapeutics Inc
13/10/202007:40Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:AKCAAkcea Therapeutics Inc
13/10/202007:39Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or ...NASDAQ:AKCAAkcea Therapeutics Inc
13/10/202007:39Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:AKCAAkcea Therapeutics Inc
12/10/202008:00PR Newswire (US)Ionis Pharmaceuticals completes acquisition of Akcea TherapeuticsNASDAQ:AKCAAkcea Therapeutics Inc
21/09/202012:56Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:AKCAAkcea Therapeutics Inc
18/09/202002:00Business WireWAYLIVRA▼® (volanesorsen), the First & Only Therapy for FCS, an Ultra-Rare & Life-Threatening Condition, to Be Available o...NASDAQ:AKCAAkcea Therapeutics Inc
15/09/202005:16Edgar (US Regulatory)Statement of Ownership: Private Transaction (sc 13e3)NASDAQ:AKCAAkcea Therapeutics Inc
14/09/202016:25Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:AKCAAkcea Therapeutics Inc
14/09/202016:12Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:AKCAAkcea Therapeutics Inc
01/09/202016:16Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:AKCAAkcea Therapeutics Inc
01/09/202015:19Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:AKCAAkcea Therapeutics Inc
31/08/202005:55PR Newswire (US)Ionis Pharmaceuticals to acquire remaining stake in Akcea TherapeuticsNASDAQ:AKCAAkcea Therapeutics Inc
29/08/202003:00PR Newswire (US)Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020NASDAQ:AKCAAkcea Therapeutics Inc
29/08/202002:30PR Newswire (US)Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020NASDAQ:AKCAAkcea Therapeutics Inc
24/08/202006:00PR Newswire (US)Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020NASDAQ:AKCAAkcea Therapeutics Inc
18/08/202006:00PR Newswire (US)Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020NASDAQ:AKCAAkcea Therapeutics Inc
13/08/202006:00PR Newswire (US)Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in GermanyNASDAQ:AKCAAkcea Therapeutics Inc
04/08/202015:05PR Newswire (US)Akcea Reports Financial Results and Highlights for Second Quarter 2020NASDAQ:AKCAAkcea Therapeutics Inc
22/07/202006:00PR Newswire (US)Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyl...NASDAQ:AKCAAkcea Therapeutics Inc
21/07/202006:00PR Newswire (US)Akcea Therapeutics to Hold Second Quarter 2020 Financial Results WebcastNASDAQ:AKCAAkcea Therapeutics Inc
20/07/202006:00PR Newswire (US)Akcea Appoints New Senior Vice President, Global Medical AffairsNASDAQ:AKCAAkcea Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AKCA

Su Consulta Reciente

AMEX
BSR
Beacon Selective Risk ETF
NASDAQ
AAWXLXX
Citigroup Global Markets...
NYSE
O
Realty Income
NYSE
GHI
Greystone Housing Impact...
LSE
0N6V
Burgenland
NYSE
PGS
Petro Geo
LSE
BSE
Base Resources
BOV
GUAR3Q
GUARARAPES ON
BOV
SBFG3R
Grupo SBF ON
LSE
0FHS
Olvi Oyj
LSE
0LLQ
Vaneck Vectors Vietnam Etf
LSE
DGI
Dg Innovate
EU
NEX
Nexans
NYSE
DBL
Doubleline Opportunities...
LSE
SMTP
Summit Properties
ASX
KGLN
KGL Resources
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados